OCTOBER 31, 2022

The Regueiro Report

Endoscopic Remission Bodes Well in UC; 2 Effective Biologics for Crohn’s Disease

Miguel Regueiro, MD
Professor of Medicine Chair of the Digestive Disease & Surgery Institute
Cleveland Clinic, Cleveland
image

The concept of “treat-to-target” isn’t new among physicians who treat inflammatory bowel disease, but over time our target has shifted. Previously, we only focused on symptoms: reducing diarrhea and bleeding levels in patients with ulcerative colitis. This symptom-only approach meant that our treatment targets were subjective. For instance, it’s